PineTree Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
767C Concord Ave, Cambridge, Massachuset...Phone Number
(857) 654-4850Website
www.pinetreetx.comRevenue
$9.1 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
2
About PineTree Therapeutics
Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor platform enables selective degradation of membrane-bound and extracellular proteins, offering a differentiated mechanism of action and durable therapeutic benefit. Pinetree is also advancing trispecific degraders and ADC-integrated platforms, and has entered strategic partnerships, including a licensing agreement with AstraZeneca.Explore more
PineTree Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PineTree Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once PineTree Therapeutics has new funding data
Click to see if PineTree Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at PineTree Therapeutics
Product Launch: Get notified when PineTree Therapeutics launches new products
Earning: See what the market has to say on PineTree Therapeutics recently announced quarterly report
Check out if PineTree Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
PineTree Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if PineTree Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined PineTree Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to PineTree Therapeutics
Compare insights from companies similar to PineTree Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PineTree Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
PineTree Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about PineTree Therapeutics.
PineTree Therapeutics financials insights
Gather financial insights about PineTree Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$23.5M
2024
Series A
$17M
PineTree Therapeutics Tech Stack
A closer look at the technologies used by PineTree Therapeutics
Most Recent Scoops
Open Position
Open Position
Hiring Plans
PineTree Therapeutics has more open roles in Human Resources than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
PineTree Therapeutics News & Media
Pinetree Therapeutics Closes $17 Million in Series A Funding to Advance AbReptor™ Protein Degradation Platform and Portfolio Programs
New investment supports continued development of multispecific antibody degraders for oncology and other therapeutic areas CAMBRIDGE, Mass., July 30, 2024 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree" or the "Company"), an emerging biotechnology company pioneering...Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca
Pinetree to receive up to $45 million in upfront and near-term payments, with a total deal value of over $500 million including potential additional development and commercial milestone payments CAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree" or the...Pinetree Therapeutics Announces Two Appointments to Strengthen its Scientific Leadership
Dr. Pamela Trail joins Scientific Advisory Board Dr. John Majercak appointed as Chief Technology Officer CAMBRIDGE, Mass., May 31, 2023 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree" or the "Company"), an emerging and award winning biotechnology company pioneering next generation...PineTree Therapeutics Inks $23.5M Series A-1
CAMBRIDGE, MA, PineTree Therapeutics announced that the company has raised $23.5 million for Series A1 funding.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PineTree Therapeutics
Sign Up For FreeTo access detailed company insights
Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor platform enables selective degradation of membrane-bound and extra... Read More
